




RECEIVED
OCT 18 2002
TECH CENTER 1600
PATENT
TECH CENTER 1600
10/23/02
No. 300622005210

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on October 7, 2002.


Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Robert MCDANIEL

Serial No.: 09/991,448

Filing Date: November 16, 2001

For: PRODUCTION OF 8, 8A-DIHYDROXY-
6-DEOXYERYTHRONOLIDE B

Examiner: To Be Assigned

Group Art Unit: 1625

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Numbers 09/768,927, filed January 23, 2001, now United States Patent Number 6,388,099, and 09/428,517, filed October 28, 1999, now United States Patent Number 6,251,636 and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This application is a Divisional of United States Serial Number 09/768,927, filed January 23, 2001, now United States Patent Number 6,388,099, and is a Continuation-in-Part of United States Serial Number 09/428,517, filed October 28, 1999, now United States Patent Number 6,251,636, and claims the benefit of the filing dates of United States Provisional Application Serial Numbers 60,177,660, filed January 27, 2000; 60/120,254, filed February 16, 1999; and 60/106,100, filed October 29, 1998.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of * is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been

made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **300622005210**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: October 7, 2002

Respectfully submitted,

By:



Susan B. Lynch
Registration No. 51,979

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7912
Facsimile: (858) 720-5125

<p>Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i></p> <p>O I P E S C I E N C E OCT 15 2002 P A T E N T & T R A D E M A R K O F F I C E</p>	Docket Number 300622005210		Application Number 09/991,448
	Applicant Robert McDANIEL		
	Filing Date November 16, 2001	Group Art Unit 1625	
	Mailing Date October 7, 2002		

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/1956	2,757,123	Sobin et al.	536	7.2	
	2.	09/1997	5,672,491	Khosla et al.	435	148	
	3.	01/1998	5,712,146	Khosla et al.	435	252.35	
	4.	10/1999	5,962,290	Khosla et al.	435	183	
	5.	12/1999	6,004,787	Katz et al.	435	183	
	6.	03/2000	6,033,883	Barr et al.	435	148	
	7.	05/2000	6,063,561	Katz et al.	435	4	
	8.	05/2000	6,066,721	Khosla et al.	536	23.1	
	9.	01/2001	6,177,262	Ziermann et al.	435	76	
	10.	03/2001	6,200,813	Katz et al.	435	477	
	11.	06/2001	6,251,636	Betlach et al.	435	76	
	12.	08/2001	6,271,255	Leadlay et al.	514	450	
	13.	08/2001	6,274,560	Khosla et al.	514	29	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	14.		WO 98/41315	WIPO			
	15.	04/1999	WO 99/05283	WIPO			
	16.	05/2000	WO 00/026349	WIPO			
	17.	04/2001	WO 01/27284	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	18.	Betlach et al., Biochemistry (1998) 37:14937-14942

EXAMINER: _____ DATE CONSIDERED: _____

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

OCT 15 2002

Docket Number 300622005210	Application Number 09/991,448
Applicant	Robert McDANIEL
Filing Date November 16, 2001	Group Art Unit 1625
Mailing Date October 1, 2002	

19.	Bisang et al., Nature (1999) 401:502-505
20.	Genbank Accession No. L09654, April 1996
21.	Haydock et al., Mol. Gen. Genet. (1991) 230:120-128
22.	Hopwood, Chem. Rev. (1997) 97:2465-2497
23.	Hu et al., Molecular Microbiology (1994) 14(1):163-172
24.	Jacobsen et al., Science (1997) 277:367-369
25.	Kakavas et al., J. of Bacteriology (1997) 179(23):7515-7522
26.	Kao et al., Science (1994) 265:509-512
27.	Katz et al., Ann. Rev. Microbiol. (1993) 47:875-912
28.	Merson-Davies et al., Mol. Microbiol. (1994) 13:349-355
29.	Olano et al., Mol. Gen. Genet. (1998) 259:299-308
30.	Oliynyk et al., Chemistry & Biology (1996) 6:833-839
31.	Patterson et al., CA (1988) 109:129535
32.	Quiros et al., Mol. Microbiol. (1998) 28:1177-1185
33.	Rodriguez et al., FEMS Microbiol. Lett. (1995) 127:117-120
34.	Schwecke et al., PNAS (1995) 92:7839-7843
35.	Shah et al., CA (2000) 133:291766
36.	Spagnoli et al., J. Antibiotics (1983) 36:365-375
37.	Stassi et al., J. Bacteriol. (1993) 175:182-189
38.	Swan et al., Molec. Gen. Genet. (1994) 242:358-362
39.	Tang et al., Chem. and Biol. (1999) 6:553-558
40.	Tatsuta et al., J. Antibiotics (1990) 43:909-911
41.	Weber et al., Science (1991) 252:114-117
42.	Witkowski et al., Biochemistry (1999) 38(36):11643-11650
43.	Xue et al., Chem. and Biol. (1998) 5:661-667
44.	Xue et al., PNAS (1998) 95:12111-12116
45.	Xue et al., Proc. Natl. Acad. Sci. USA (1999) 96:11740-11745
46.	Zierman et al., Biotechniques (1999) 26:106-110

TECH CENTER 1600/2900
RECEIVED
OCT 18 2002

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.